ArticleJournal of investigative medicine : the official publication of the American Federation for Clinical Research2021
Efficacy of patent foramen ovale closure for treating migraine: a prospective follow-up study.
Article in Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Patent Foramen Ovale Closure for Treating Migraine: A Meta-Analysis.Journal of interventional cardiology · 2022Pooled it
- Fully biodegradable versus nitinol occluder devices for transcatheter patent foramen ovale closure: a systematic review.Global cardiology science & practice · 2026Review
- To dig oneself into a hole or to dig the tunnel to the core? A study on the Swartz sheath support strategy for patent foramen ovale closure in migraine patients.Journal of translational internal medicine · 2026Article
- Transcatheter Patent Foramen Ovale Closure and Complete Remission of Migraine in Children: A Single-Center Retrospective Cohort Study.Pediatric cardiology · 2026Article
- Right-to-left shunt is associated with reduced cerebral vascular reactivity in migraine patients with aura.Frontiers in neurology · 2026Observational
- Preliminary study on the application of percutaneous patent foramen ovale (PFO) closure in the treatment of children with PFO and severe migraine.Translational pediatrics · 2025Article
- Right Heart Contrast Echocardiography Microbubble Count and Migraine Severity: A Dose-Effect Relationship Study.Clinical cardiology · 2025Article
- Clinical characteristics and short-term outcomes of migraine with patent foramen ovale: a comparative study.European journal of medical research · 2025Article
- Effects of patent foramen ovale in migraine: a metabolomics-based study.The Journal of physiology · 2025Article
- The safety, efficacy, and influencing factors of biodegradable versus metallic occluders in the treatment of migraine patients with patent foramen ovale.Frontiers in neurology · 2025Article
- Rationale and design of the SPRING trail: effectivity and safety of Pfo closuRe vs medIcine in alleviatiNg migraine, a multicenter, randomized and open-label trail.BMC cardiovascular disorders · 2024Article
- A study on the correlation of the asymmetric regulation between the periaqueductal gray and the bilateral trigeminal nucleus caudalis in migraine male rats.The journal of headache and pain · 2023Article
- Effect of Interventional Therapy Unexplained Dizziness and Relationship Between Dizziness Handicap Inventory and Right-to-Left Shunt Grading.International journal of general medicine · 2023Article
- The Influence of Patent Foramen Ovale on the Clinical Features of Migraine without Aura: A Cross-Sectional Study.International journal of general medicine · 2023Article
- Efficacy and safety of transesophageal ultrasound-guided patent foramen ovale closure for migraine in adolescents.Frontiers in pediatrics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the potential of percutaneous patent foramen ovale (PFO) closure to improve the headache in patients with migraine and PFO, and discuss the difference between the randomized controlled trials (RCTs) and the single-center studies. Patients of migraine with a large shunt of PFO, who experienced ≥2 headache attacks per month and failed ≥2 categories of standardized medication, underwent PFO closure in First Affiliated Hospital of Xi'an Jiao Tong University. The clinical outcomes, including frequency and duration of headache attacks, Headache Impact Test (HIT-6) score, and Visual Analogue Scale (VAS) score, were evaluated at 3, 6, and 12 months of follow-up after the PFO closure. The different efficacies of the clinical outcomes between patients with and without aura as well as different grades of PFO were also evaluated, respectively. 134 patients with migraine (39 male and 95 female) with PFO were enrolled, whose average age was 39.21±11.37 years. After PFO closure, there was a significant reduction in frequency and duration of headache attacks, HIT-6 score, and VAS score at 3, 6, and 12 months' follow-up (p<0.001). Migraine was completely relieved in 54 (40.30%) patients during 12 months' follow-up. The frequency of migraine was reduced by >50% in 44 (32.84%) patients at 3 months' follow-up and increased to 48 (35.82%) at 12 months' follow-up. 31.03% patients remained residual shunt after 6 months of closure with varying improvements of headache. This study confirmed that PFO closure can effectively reduce frequency and duration of migraine and improve quality of life, but the definitive indications and long-term effect still need further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.